Caris Life Sciences (CAI) director Johansen granted 13,192 restricted stock units

Rhea-AI Filing Summary

JOHANSEN LAURA I reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences, Inc. reported that director Laura I. Johansen received a grant of 13,192 shares of Common Stock in the form of restricted stock units on 2026-08-14. The award was recorded at $0.00 per share and increased her directly held position to 343,897 shares. According to the accompanying note, these restricted stock units vest in accordance with the applicable grant agreement.

Insider Trade Summary

Net Buyer: 13,192 shares

Net Buy 1 txn

Insider JOHANSEN LAURA I

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	13,192	$0.00	$0.00

Holdings After Transaction: Common Stock — 343,897 shares (Direct)

Footnotes (1)

1. F1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Key Figures

RSU grant size: 13,192 shares Per-share transaction price: $0.00 per share Shares held after transaction: 343,897 shares +1 more

4 metrics

RSU grant size 13,192 shares Restricted stock unit award of Common Stock on 2026-08-14

Per-share transaction price $0.00 per share Reported price for the 13,192-share restricted stock unit grant

Shares held after transaction 343,897 shares Total direct Common Stock holdings after the grant to Laura I. Johansen

Number of acquire-type transactions 1 transaction Single non-derivative acquisition coded as a grant/award (A)

Key Terms

restricted stock units, grant, award, or other acquisition, non-derivative

3 terms

restricted stock units financial

"Represents an award of restricted stock units which vest in accordance"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

non-derivative financial

"transaction_type: non-derivative"

FAQ

What did Caris Life Sciences (CAI) disclose about Laura I. Johansen in this Form 4?

Caris Life Sciences disclosed that director Laura I. Johansen received a grant of 13,192 restricted stock units of Common Stock on 2026-08-14, increasing her directly held shares to 343,897.

How many shares were granted to Laura I. Johansen in the CAI Form 4 filing?

The filing shows a grant of 13,192 shares of Common Stock in the form of restricted stock units. These units vest under the applicable grant agreement and were reported at a per-share transaction price of $0.00.

What is Laura I. Johansen’s total direct shareholding in CAI after this transaction?

After the reported grant, Laura I. Johansen directly holds 343,897 shares of Caris Life Sciences Common Stock. This figure reflects her position following the 13,192-share restricted stock unit award disclosed in the Form 4.

Was the CAI Form 4 transaction a purchase or a grant for Laura I. Johansen?

The transaction was reported as a grant or award acquisition of 13,192 restricted stock units, coded as “A”. It is categorized as a non-derivative acquisition, not an open-market purchase or sale.

Do the restricted stock units granted to Laura I. Johansen in CAI vest immediately?

No. A footnote states the 13,192-share award represents restricted stock units that vest in accordance with the applicable grant agreement. The specific vesting schedule is not detailed in this disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 05:40 PM Accepted by SEC EDGAR 08/14/2026 - 05:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHANSEN LAURA I

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TEXAS 75039

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		A		13,192(1)	A	$0	343,897	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)